DFN 15

Drug Profile

DFN 15

Alternative Names: DFN-15A; DFN-15B

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Promius Pharma
  • Developer Dr Reddys Laboratories
  • Class Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 24 Jun 2017 Dr. Reddy's Laboratories initiates enrolment in a phase I trial for Migraine (In volunteers) in USA (PO) (NCT03282838)
  • 01 Dec 2016 Dr. Reddy's Laboratories initiates a phase III trial for Migraine in USA (PO) (NCT03009019)
  • 01 Dec 2016 Phase-III clinical trials in Migraine in USA (PO) (NCT03006276)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top